内容紹介
Summary
Objective: A retrospective analysis on carboplatin(CBDCA)/nanoparticle albumin-bound paclitaxel(nab-PTX)combination chemotherapy was conducted in patients with non-small-cell lung cancer(NSCLC)to evaluate both the efficacy and toxicity based on age, treatment line, histology, and underlying diseases. Subjects: A total of 27 patients with advanced or recurrent NSCLC following surgery who received CBDCA/nab-PTX as first- and second-line combination chemotherapy, respectively, were investigated from March 2013 to December 2015. Results: The overall response rate, median progression-free survival, and median overall survival of all patients were 37.0%, 5.5 months, and 11.4 months, respectively. With regard to toxicity, 3.7% and 14.8% of all patients had peripheral disorder and interstitial lung disease(ILD), respectively. Treatment-related deaths were not observed. No difference in the efficacy based on age, treatment line, histology, and underlying diseases was observed. Conclusion: CBDCA/nab-PTX combination chemotherapy was safe for elderly patients and those with ILD. However, the occurrence of new interstitial lung lesions should be carefully considered.
要旨
目的: 非小細胞肺癌に対するcarboplatin(CBDCA)/nanoparticle albumin-bound paclitaxel(nab-PTX)併用療法の有効性・安全性を年齢,治療次数,組織や基礎疾患で分け,後方視的に評価を行った。対象: 2013年3月～2015年12月の間に,CBDCA/nab-PTX併用療法を一次治療または二次治療で施行した進行・術後再発の非小細胞肺癌患者27例。結果: 全症例の全奏効率は37.0%で,無増悪生存期間中央値5.5か月,全生存期間中央値は11.4か月であった。末梢神経障害を3.7%,間質性肺障害を14.8%に認めたが,治療関連死は認めなかった。年齢,治療次数,組織や基礎疾患で治療効果に差はみられなかった。結論: CBDCA/nab-PTX併用療法は高齢者に対しても比較的安全に施行可能であった。また,間質性肺疾患を基礎疾患にもつ症例においても有害事象は忍容し得ると考えられたが,化学療法中は間質性肺障害の発症に注意が必要である。
目次
Objective: A retrospective analysis on carboplatin(CBDCA)/nanoparticle albumin-bound paclitaxel(nab-PTX)combination chemotherapy was conducted in patients with non-small-cell lung cancer(NSCLC)to evaluate both the efficacy and toxicity based on age, treatment line, histology, and underlying diseases. Subjects: A total of 27 patients with advanced or recurrent NSCLC following surgery who received CBDCA/nab-PTX as first- and second-line combination chemotherapy, respectively, were investigated from March 2013 to December 2015. Results: The overall response rate, median progression-free survival, and median overall survival of all patients were 37.0%, 5.5 months, and 11.4 months, respectively. With regard to toxicity, 3.7% and 14.8% of all patients had peripheral disorder and interstitial lung disease(ILD), respectively. Treatment-related deaths were not observed. No difference in the efficacy based on age, treatment line, histology, and underlying diseases was observed. Conclusion: CBDCA/nab-PTX combination chemotherapy was safe for elderly patients and those with ILD. However, the occurrence of new interstitial lung lesions should be carefully considered.
要旨
目的: 非小細胞肺癌に対するcarboplatin(CBDCA)/nanoparticle albumin-bound paclitaxel(nab-PTX)併用療法の有効性・安全性を年齢,治療次数,組織や基礎疾患で分け,後方視的に評価を行った。対象: 2013年3月～2015年12月の間に,CBDCA/nab-PTX併用療法を一次治療または二次治療で施行した進行・術後再発の非小細胞肺癌患者27例。結果: 全症例の全奏効率は37.0%で,無増悪生存期間中央値5.5か月,全生存期間中央値は11.4か月であった。末梢神経障害を3.7%,間質性肺障害を14.8%に認めたが,治療関連死は認めなかった。年齢,治療次数,組織や基礎疾患で治療効果に差はみられなかった。結論: CBDCA/nab-PTX併用療法は高齢者に対しても比較的安全に施行可能であった。また,間質性肺疾患を基礎疾患にもつ症例においても有害事象は忍容し得ると考えられたが,化学療法中は間質性肺障害の発症に注意が必要である。